MT-125 — catalyst calendar
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-10-31 in 3mo
ESTIMATED |
READOUT
A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients
Phase 1/2 · Glioblastoma (GBM) |
Myosin Therapeutics Inc. | MT-125 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|